Do you want to read an article? Please log in or register.
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
Lung, Respiratory and Thoracic Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Front Oncol
Gros L, Szturz P, Diciolla A, Kirchner V, Peters S, Schaefer N, Hubner M, Digklia A
doi: 10.3389/fonc.2021.704295
Lung, Respiratory and Thoracic CancerLymphoma
Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma
JAMA Oncol.
Hung YP, Dong F, Watkins JC, Nardi V, Bueno R, Dal Cin P, Godleski JJ, Crum CP, Chirieac LR
doi: 10.1001/
Lung, Respiratory and Thoracic Cancer
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
Ann Oncol.
Metaxas Y, Früh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R, Swiss Group for Clinical Cancer Research (SAKK).
doi: 10.1016/j.annonc.2019.12.009.
WCLC 2020
Lung, Respiratory and Thoracic Cancer
Malignant Mesothelioma
Fennel D et al. 2021. Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. Oral presentation presented at: WCLC 2020; 28−31 January 2021.
Lymphoma
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Lancet Oncol.
Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K
doi: 10.1016/S1470-2045(20)30225-4.
Lung, Respiratory and Thoracic CancerMultiple Myeloma (MM)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group
Arch Pathol Lab Med.
Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Sallé F, Gibbs A, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, Wick MR
doi: 10.5858/arpa.2017-0124-RA.
Lung, Respiratory and Thoracic CancerRadio-Oncology
Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting
J Thorac Oncol.
Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG 3rd, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB 2nd, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH Jr, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK
doi: 10.1016/j.jtho.2019.08.012.
Lymphoma
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Lancet Haematol.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA
doi: 10.1016/S2352-3026(20)30120-4.
Lung, Respiratory and Thoracic Cancer
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
Lancet Oncol
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G, CONFIRM trial investigators.
doi: 10.1016/S1470-2045(21)00471-X